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10.1126/sciadSpinal muscular atrophy with respiratory distress type 1 (SMARD1) is an autosomal recessive motor neuron disease
affecting children. It is caused by mutations in the IGHMBP2 gene (11q13) and presently has no cure. Recently,
adeno-associated virus serotype 9 (AAV9)–mediated gene therapy has been shown to rescue the phenotype of
animal models of another lower motor neuron disorder, spinal muscular atrophy 5q, and a clinical trial with this
strategy is ongoing. We report rescue of the disease phenotype in a SMARD1 mouse model after therapeutic de-
livery via systemic injection of an AAV9 construct encoding the wild-type IGHMBP2 to replace the defective gene.
AAV9-IGHMBP2 administration restored protein levels and rescued motor function, neuromuscular physiology, and
life span (450% increase), ameliorating pathological features in the central nervous system, muscles, and heart. To
test this strategy in a human model, we transferred wild-type IGHMBP2 into human SMARD1-induced pluripotent
stem cell–derived motor neurons; these cells exhibited increased survival and axonal length in long-term culture.
Our data support the translational potential of AAV-mediated gene therapies for SMARD1, opening the door for
AAV9-mediated therapy in human clinical trials.INTRODUCTION
Spinal muscular atrophy with respiratory distress type 1 (SMARD1,
OMIM 604320), also called distal spinal muscular atrophy type 1, is
a fatal genetic motor neuron disease with infantile onset and without
any effective therapy (1, 2). It is the second most frequent form of spinal
muscular atrophy after spinal muscular atrophy linked to chromosome
5q (SMA). SMARD1 is characterized by respiratory distress, usually
within the first year of life, with initially distal and later generalized
muscle weakness that leads to early death (2, 3). The disease results from
loss-of-function mutations in the gene encoding the immunoglobulin
m-binding protein 2 (IGHMBP2) (4, 5). IGHMBP2 is an adenosine
triphosphatase/helicase motif–containing DNA-binding protein that
controls several nuclear, RNA, and translation processes; its function
remains largely unclear. A splice site mutation in murine Ighmbp2
causes a neuromuscular disorder in the nmd mouse similar to the hu-
man disease, thus representing an animal model of SMARD1 (6).
Although how IGHMBP2 reduction/loss leads to selective motor
neuron degeneration and to the disease phenotype in rodents and
humans is unknown, gene therapy is a potential curative therapeutic
strategy because it provides a functional gene, thereby addressing the
cause of the disease. The final objective in the treatment of neurolog-
ical disorders is to achieve global distribution of the therapeutic agent
via minimally invasive delivery. Adeno-associated virus serotype 9
(AAV9), a recently isolated serotype, displays central nervous system
(CNS) tropism and crosses the blood-brain barrier after systemic and
intrathecal administration (7, 8). Moreover, systemically delivered
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Recent gene therapies aiming at SMN1 AAV9–mediated delivery in
SMA mice and large animals, conducted with systemic or cerebrospinal
fluid injection, seem promising and may provide some of the most ef-
ficacious therapeutic possibilities for SMA patients (10–13). The Food
and Drug Administration recently approved a phase 1 clinical trial to
evaluate the safety and efficacy of intravenous delivery of AAV9 human
SMN in patients with type I SMA, with an age range of 0 to 9 months.
This trial (NCT02122952, www.clinicaltrial.gov) started enrolling pa-
tients in April 2014; three patients have been injected (14). No gene ther-
apy strategy has yet been attempted for SMARD1, and few other
therapeutic approaches have been tested. We previously performed the
first experimental investigations using cell therapy in nmd mice (15–17).
Here, we provide preclinical proof-of-principle data that demonstrate
the high efficacy of IGHMBP2 gene therapy in the SMARD1 mouse
model as well as in an in vitro model of the human disease, providing
strong evidence for establishing a clinical trial of AAV9-mediated
IGHMBP2 gene therapy. In the nmd mice investigated here, AAV9-
IGHMBP2 gene transfer via systemic injection resulted in unprecedented
improvements in motor function and survival. Wild-type IGHMBP2
rescued the disease phenotype in human SMARD1 motor neurons
in vitro. Furthermore, we established an AAV9-IGHMBP2 construct
and a preclinical administration protocol to serve as a template for future
clinical trials for SMARD1 and other genetic diseases of motor neurons.RESULTS
AAV9-IGHMBP2 can increase protein levels in
wild-type mice
We generated a plasmid harboring a single-stranded AAV expression
cassette carrying the wild-type human IGHMBP2 complementary DNA
(cDNA) [National Center for Biotechnology Information (NCBI) acces-
sion number NM_002180] coding sequence under the control of the1 of 10
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(fig. S1A) (AAV9-IGHMBP2). We transfected human embryonic kid-
ney (HEK) 293 cells with the plasmid, which resulted in up-regulated
expression of IGHMBP2 protein (fig. S1, B and C). Next, we evaluated
its potency in C57BL/6 mice by delivering 1 × 1010 vector genomes (vg)
of AAV9-IGHMBP2 to the gastrocnemius muscle via intramuscular
injection. Two weeks after injection, IGHMBP2 levels were clearly detect-
able in the injected muscle by Western blotting (fig. S1, D and E).
Administration of AAV9-IGHMBP2 results in high levels of
expression in the nmd CNS
To define the transduction efficiency of AAV9, we injected nmd and
wild-type pups at postnatal day 1 (P1) with AAV9 encoding green fluo-
rescent protein (GFP) (AAV9-GFP), AAV9-IGHMBP2, or AAV9 with
no inserted gene (AAV9-null) intravenously into the facial vein for a to-
tal dose of 5 × 1011 vg per pup (Fig. 1A). AAV9-GFP injection resulted
in widespread central nervous system (CNS) transduction, particularlyNizzardo et al. Sci. Adv. 2015;1:e1500078 13 March 2015in the spinal cord, as indicated by the fluorescence intensity of GFP in
the parenchyma (Fig. 1B). SMI32-positive motor neurons were highly
positive for GFP after AAV9-GFP injection (Fig. 1C). We observed
that 40% of lumbar spinal motor neurons expressed GFP 2 weeks after
injection. Thus, intravenous injection in P1 mice led to the broad and
extensive transduction of the spinal cord by the genetic construct.
To measure the increase in IGHMBP2 expression after AAV9 ad-
ministration, we treated a cohort of wild-type and nmd mice at P1
with a single intravenous injection of AAV9-IGHMBP2 or AAV9-null
(5 × 1011 vg per pup). AAV9-IGHMBP2 treatment resulted in a twofold
increase in IGHMBP2 protein levels in spinal cord compared with
AAV9-null treatment (P < 0.01; Fig. 1, D and E).
AAV9-IGHMBP2 therapy protects SMARD1 motor neurons
and axons
To evaluate the impact of gene therapy on neuropathological SMARD1
hallmarks, we analyzed spinal cord motor neurons and ventral spinal nerveroots in 4-week-old mice. We detected a
severe loss of motor neurons in AAV9-
null-nmdmice compared to wild-type mice
(Fig. 2). In contrast, in association with the
increase in IGHMBP2 expression, we de-
tected consistent preservation of the number
of motor neurons in AAV9-IGHMBP2-
nmdmice (Fig. 2A). In all analyzed sections,
the number of motor neurons in AAV9-
IGHMBP2-nmd mice was significantly
higher than that in AAV9-null-nmd litter-
mates (P < 0.01; Fig. 2B).
Prominent motor neuron degeneration
significantly reduced the number and over-
all diameter of L4-L5 ventral nerve roots in
AAV9-null-nmdmice (Fig. 2D). The same
reduction was detected in all lumbar ven-
tral roots analyzed (Fig. 2D). Significant
improvement occurred after treatment;
4-week-old AAV9-null-nmdmice displayed
fewer myelinated axons, whereas the num-
ber of myelinated axons in the ventral roots
of AAV9-IGHMBP2-nmd mice was sig-
nificantly restored (P < 0.01; Fig. 2C).
Wild-type gene delivery
ameliorates defects in
neuromuscular junctions
Mutant nmd mice had denervated motor
end plates that correspond to motor neu-
ron degeneration (Fig. 3, A and B). In
these motor endplates, subsynaptic clefts
and folds were not present and/or did not
mature, indicating degeneration (Fig. 3A).
We observed this pathological hallmark
of SMARD1 disease in nearly 50% of
presynaptic termini from the quadriceps,
gastrocnemius, and diaphragm of AAV9-
null-nmd animals (Fig. 3B). On the other
hand, nearly 90% of neuromuscular junc-
tions (NMJs) of the AAV9-IGHMBP2-nmdFig. 1. AAV9-GFP and AAV9-IGHMBP2 efficiently transduce tis-
sues in nmd mice. (A) In vivo experimental design: newborn (P1)
nmd mice were injected with AAV9-GFP, AAV9-IGHMBP2, or AAV9-
11null for a total dose of 5 × 10 vg. (B) Injection of AAV9-GFP in
wild-type (WT) animals resulted in GFP expression (green) within the spinal cord 2 weeks after injection.
(C) Colocalization of GFP (green) with SMI32 (red) demonstrated that motor neurons were efficiently trans-
duced. (D) Western blots of spinal cords revealed increased levels of IGHMBP2 in AAV9-IGHMBP2-nmd
versus AAV9-null-nmd animals. (E) Quantification of IGHMBP2 levels in the spinal cord. Values are means
± SEM of IGHMBP2:b-actin expression levels (n = 5), *P < 0.01. Scale bars, 500 mm (B) and 50 mm (C).2 of 10
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(Fig. 3, A and B). We observed a correct “pretzel-like” structure on
postsynaptic NMJs that reflected the presence of a functional network
of acetylcholine receptors in AAV9-IGHMBP2-nmd mice (Fig. 3A).
AAV9-IGHMBP2 improves the size of myofibers in skeletal
muscles and heart
Nmdmice typically display muscle fiber atrophy in gastrocnemius and
diaphragm muscles, mimicking the human pathological condition in
SMARD1 (2, 18). These aspects are due to denervation and to myo-
pathic changes caused by IGHMBP2 reduction. We confirmed severe
myopathic changes, including a wide variability in fiber size, centralized
nuclei, fatty infiltration, and necrotic myofibers, in the quadriceps and
diaphragm of AAV-null-nmd mice (Fig. 3C).
In contrast, AAV9-IGHMBP2 treatment positively affected muscle
fiber morphology and organization and significantly increased myofiber
caliber in the quadriceps, gastrocnemius, and diaphragm (P < 0.001;Nizzardo et al. Sci. Adv. 2015;1:e1500078 13 March 2015Fig. 3, C and D). Because a previous study
uncovered signs of cardiomyopathy in
nmd mice (19), we performed pathologi-
cal analysis and weight measurement of
the heart. AAV-null-nmd mice had mild
cardiac hypertrophy that was slightly im-
proved, even if not statistically significant,
with AAV-IGHMBP2 treatment, as mea-
sured by the ratio of heart weight to body
weight (fig. S2).
AAV9-IGHMBP2 therapy rescues
the neuromuscular phenotype
and increases the survival of
SMARD1 mice
We evaluated whether AAV9-IGHMBP2
treatment improved the disease pheno-
type and extended survival in nmd mice.
Functional recovery was assessed in all
animal groups through blind evaluation
of their general appearance, weight, neu-
romuscular function, and survival after
treatment (Fig. 4). The first clinical symp-
toms in nmdmice presented in the second
postnatal week when mice rapidly devel-
oped muscle weakness in the hindlimbs,
which were contracted, causing impaired
locomotor activity. This limited limb ex-
tension made standing on all four limbs
impossible. Suspended by the tail, homo-
zygous affected mice were not able to
clench their hindlimbs and could not grip
a cage cover (Fig. 4A). As the disease pro-
gressed, this weakness worsened to in-
clude the forelimbs and trunk muscles,
as previously reported (18–20).
Gross examination of AAV9-IGHMBP2-
nmd animals revealed an improved ap-
pearance relative to AAV9-null-nmdmice;
treated animals were more similar to wild-
type animals (movie S1). Most AAV9-IGHMBP2-nmd mice exhibited no overt signs of motor dysfunction
and were nearly indistinguishable from their wild-type littermates
(movie S1); they were able to walk, explore the environment, and per-
form various behaviors like wild-type mice. At 3 weeks, AAV9-IGHMBP2-
nmd mice could splay their hindlimbs (Fig. 4A). In contrast, their
AAV9-null-nmd littermates showed muscle degeneration and clear
contracture of the hindlimbs (Fig. 4A).
AAV9-null-nmd mice were paralyzed by the age of 5 weeks and
failed to remain on the accelerating rotarod test for more than a
few seconds (P < 0.0001 versus wild-type siblings) (Fig. 4B), as previ-
ously described (19). In contrast, AAV9-IGHMBP2-nmd mice could
perform the rotarod test throughout their lifetimes and did not display
a hindlimb clasping. At each time point, the performance of AAV9-
IGHMBP2-nmdmice was superior to that of AAV9-null-nmd animals
(P < 0.0001 versus AAV9-null-nmdmice; Fig. 4B). The growth rate of
AAV9-IGHMBP2-nmd mice, as measured by mean body weight, in-
creased compared to that of AAV9-null-nmdmice and was significantlyFig. 2. AAV9-IGHMBP2 increases motor neuron and axon number. (A) Representative motor neuron
pools in the lumbar segment of the spinal cords of AAV9-IGHMBP2-nmd, AAV9-null-nmd, and WT mice
at 4 weeks of age. (B) Quantification of motor neurons in the lumbar spinal cords of treated mice and
WT mice (mean ± SD) at 4 weeks of age (n = 6 per group per time point). (C) Quantification of myelinated
axons in the L4 anterior roots in WT, AAV9-IGHMBP2-nmd, and AAV9-null nmdmice (mean ± SD) at 4 weeks
of age (n = 6 per group per time point). Motor neuron and myelinated axon counts significantly increased
in the AAV9-IGHMBP2 treatment group compared to the AAV9-null group (*P < 0.0001). (D) Representative
images of the L4 anterior roots of AAV9-IGHMBP2-nmd, AAV9-null-nmd, and WT mice at 4 weeks of age.
Scale bar, 50 mm (A and D).3 of 10
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week 8, P < 0.05; Fig. 4C). More striking-
ly, Kaplan-Meier survival estimates re-
vealed that AAV9-IGHMBP2-nmd mice
showed significantly increased mean life
spans (450%) compared to sibling-matched
AAV9-null-nmd mice (AAV9-IGHMBP2-
nmd, 307 ± 74 days, n = 17; AAV9-null-
nmd, 68 ± 25 days, n = 24; P = 0.0001, c2 =
26.52; Fig. 4D). Most AAV9-IGHMBP2-
nmd animals are still alive, some at more
than 300 days of age, suggesting that they
can be considered completely rescued.
AAV9-IGHMBP2 rescues the disease
phenotype of spinal motor neurons
derived from SMARD1-induced
pluripotent stem cells (iPSCs)
Our next question was whether the trans-
fer of IGHMBP2 also protected human
SMARD1 motor neurons against degen-
eration induced by the loss of IGHMBP2.
For this purpose, we used iPSCs that we generated from SMARD1
patients and healthy subjects (Fig. 5A) (17). We differentiated these
cells into motor neurons, monitoring their phenotype by immuno-
cytochemistry for motor neuronal markers. Human motor neurons
extended processes and expressed SMI32 and choline acetyltransferaseNizzardo et al. Sci. Adv. 2015;1:e1500078 13 March 2015(ChAT) (Fig. 5B). For further evaluation, we examined several features
of motor neurons that are likely relevant to SMARD1 pathogenesis,
including cell survival, axonal elongation, and growth cone formation.
At 8 weeks, SMARD1 iPSC–derived motor neurons had significantly
reduced cell numbers and axon length compared to motor neuronsFig. 3. AAV9-IGHMBP2 improves NMJs
and the size of myofibers in skeletal mus-
cles. (A and B) NMJs in the quadriceps, gas-
trocnemius, and diaphragmmuscles improved
after gene therapy. (A) Representative im-
ages of NMJs from the quadriceps of WT,
AAV9-IGHMBP2-nmd, and AAV9-null-nmd
mice. Neurofilament Ab, green; a-bungarotoxin,
red. The asterisk highlights an unoccupied NMJ.
Scale bar, 20 mm. (B) Percentage of dener-
vated NMJs in gastrocnemius, quadriceps,
and diaphragm muscles (mean ± SEM; *P <
0.001). (C and D) AAV9-IGHMBP2 treatment
influenced fiber caliber in nmd quadriceps,
gastrocnemius, and diaphragm muscles. (C)
Representative images of quadriceps and di-
aphragm muscle fibers at 4 weeks stained
with hematoxylin and eosin (H&E). Increased
numbers of perimysial and central cell nuclei
were observed in untreated nmdmice; these
numbers declined after AAV9-IGHMBP2 treat-
ment. Scale bar, 100 mm. (D) Significant re-
ductions in fiber caliber were evident in
AAV9-null-nmd mice versus control mice;
AAV9-IGHMBP2 treatment ameliorated this
effect. Values are means ± SEM.4 of 10
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derived from genetically corrected SMARD1 cells (TR-SMARD1) presented
an ameliorated phenotype, with increased cell survival at 8 weeks of
culture (P < 0.001; Fig. 5C). These improved features were linked to
increased IGHMBP2 expression; TR-SMARD1 motor neurons also
presented increased neurite lengths compared to untreated neurons
(P < 0.001; Fig. 5D). TR-SMARD1 motor neurons and their parental
iPSCs expressed IGHMBP2 at higher levels than did untreated cells, as
revealed by immunocytochemistry and Western blotting (Fig. 5, E to
G). Thus, transferring wild-type IGHMBP2 can protect human motor
neurons from SMARD1-induced degeneration.DISCUSSION
SMARD1 is a motor neuron disease caused by mutations in IGHMBP2.
Because it is due to a single gene defect and has a fatal outcome with-
out any effective cure, it could be an appropriate candidate disease for
therapeutic strategies based on gene therapy.
Here, we demonstrated the efficacy of AAV9-mediated induction
of wild-type IGHMBP2 expression, a strategy that may represent a
novel and successful therapeutic approach for SMARD1. We described
the most effective rescue of SMARD1 mice achieved with a therapeutic
treatment to date; this rescue was characterized according to motorNizzardo et al. Sci. Adv. 2015;1:e1500078 13 March 2015function, neuromuscular physiology, and survival after a single injec-
tion of AAV9-IGHMBP2. We systemically administered AAV9 vec-
tors encoding human wild-type IGHMBP2, exploiting the cutting edge
finding that AAV9 can cross the blood-brain barrier and successfully
transduce the CNS (7, 8). These results were obtained in the nmd
mouse model, which recapitulates many disease features of SMARD1
patients (1). Our study verified that the reconstitution of IGHMBP2 levels
in the CNS and in systemic organs corrected the pathological manifesta-
tions in these organs. More strikingly, we achieved the longest extensions
in survival ever reported for the nmd mouse model (increasing survival
by 450%); the phenotype of some AAV9-IGHMBP2-nmd animals was
nearly indistinguishable from that of their wild-type littermates.
Previous investigations indicated that IGHMBP2 expression, not
only in motor neurons but also in other types of cells, is required
to obtain complete functional rescue of the nmd phenotype (18, 19).
Indeed, neuron-specific expression of IGHMBP2 rescued motor neu-
ron degeneration in nmd mice, but not the cardiac and skeletal myo-
pathies that lead to the death of nmd mice (19). These data suggest an
additional role of IGHMBP2 in the conservation of muscle fibers. Sys-
temic injection allowed us to treat not only neurons and nonneuronal
cells but also muscle and heart, all of which are involved in SMARD1
pathogenesis and are target cells for SMARD1 treatment.
AAV9-IGHMBP2 treatment consistently preserved the numbers of
motor neurons and axons in SMARD1 mice, even if we achieved 40%Fig. 4. AAV9-IGHMBP2 treatment improves neuromuscular func-
tion and survival in nmd mice. (A) Representative images of AAV9-
(P < 0.0001). Error bars denote SEM. (C) The mean body weight of AAV9-
IGHMBP2-nmd mice significantly increased relative to AAV9-null-nmdIGHMBP2-nmd mice showing their capacity to extend their hindlimbs
in comparison to AAV9-null-nmd mice. (B) Rotarod test data. The per-
formance of AAV9-IGHMBP2-nmd mice was significantly improved ver-
sus AAV9-null-nmd mice, which were never able to complete the testmice (P< 0.01). Error bars show SEM. (D) Kaplan-Meier survival curves
of AAV9-IGHMBP2-nmd mice and AAV9-null-nmd mice (P < 0.0001).
For all graphs: AAV9-IGHMBP2-nmd mice, n = 17; AAV9-null-nmd mice,
n = 24.5 of 10
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Nizzardo et al. Sci. Adv. 2015;1:e1500078Fig. 5. AAV9-IGHMBP2 treatment
protects human iPSC-derived spi-
nal motor neurons from SMARD1-
induced degeneration. (A) Schematic
of the experimental strategy used to
differentiate motor neurons from iPSCs.
(B) Compared to WT (left), significant-
ly fewer SMARD1 motor neurons were
observed after long-term culture (right).
Genetic correction with IGHMBP2 in-
creased the number of SMARD1motor
neurons (TR-SMARD1, middle panel).
SMI32, green; ChAT, red; DAPI, blue.
Scale bar, 75 mm. (C) Genetic correction
(green bar) protected motor neurons
in long-term culture, increasing their
survival versus SMARD1 cells (yellow
bar) (8weeks, *P< 0.001). (D) At 8weeks,
SMARD1 motor neurons (yellow) pre-
sented shorter axons than did WT cells
(black). TR-SMARD1 (green) had longer
axons than did SMARD1 motor neu-
rons (P < 0.001). (E) IGHMBP2 staining
(green) of WT motor neurons (left),
SMARD1 motor neurons (right), and
TR-SMARD1 (middle). Nuclei were coun-
terstained with DAPI (blue). Scale bar,
70 mm. (F) Western blot of genetically
corrected SMARD1 iPSCs (TR-SMARD1)
indicated significantly increased ex-
pression of IGHMBP2 with respect
toSMARD1 cells (SMARD1). (G) Quan-
tification of IGHMBP2 levels in trans-
fected SMARD1 iPSCs (TR-SMARD1)
versus untransfected SMARD1 cells
(SMARD1). Values are means ± SEM
(*P < 0.01).13 March 2015 6 of 10
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crease in IGHMBP2 levels in various cell compartments—not only the
soma but also at the NMJ site and in other cells, such as nonneuronal
cells in the CNS and muscles in the periphery—contributes to the ob-
served increases in motor neuron survival. Indeed, IGHMBP2 delivery
repaired the abnormal architecture of pre- and postsynaptic NMJs,
which is also associated with functional improvements on the rotarod
test. Myofiber size and NMJ structure in AAV9-IGHMBP2-nmd mice
were similar to those in wild-type muscles. This result may be due to
the direct action of IGHMBP2 on NMJs, favoring the normalization
of transcription/translation in presynaptic termini, as well as to direct
IGHMBP2 action on muscle. AAV9-IGHMBP2 treatment also exerted
a positive effect on muscle fiber morphology and organization and
significantly increased myofiber caliber in the quadriceps, gastrocne-
mius, and diaphragm. Correcting defects in the CNS, heart, and mus-
cles likely facilitated the long-term survival in this animal model.
Treating dilated cardiomyopathy is an important aspect of rescuing
these animal models, an aspect that can be overlooked in humans be-
cause of the severity of CNS clinical features. The myopathy observed
in nmd mice has not been clearly detected in human SMARD1 pa-
tients, probably because severe motor neuropathy causes death before
cardiomyopathy manifestation (19). Further studies are needed to un-
derstand whether targeting other tissues and organs in addition to the
CNS is necessary in humans.
For clinical translation, the widespread transfer of the gene to the
brain and the spinal cord resulting from a peripheral injection is par-
ticularly important because it allows a minimally invasive intervention,
avoids direct injecting directly the CNS, and produces gene expression
throughout the entire CNS. Moreover, the probability of an immuno-
response against IGHMBP2 in children is relatively low, because many
SMARD1 patients have a residual amount of protein. Quantification
of this residual amount of protein is possible before treatment, for ex-
ample, in peripheral cells such as fibroblasts (21), thus allowing the eval-
uation of immunization risk if the protein is absent. Immunosuppression
with steroids can mitigate the immune response, as demonstrated with
gene therapy for Duchenne muscular dystrophy (22). Although the
AAV capsid can raise an immunoresponse, one-time gene therapy
may be suitable for the reasons discussed above; some strategies, such
as plasmapheresis, can eliminate the negative impact of antibodies
(Abs) against AAV (23).
Another advantage of AAV9-mediated gene delivery is that it leads
to long-term wild-type protein expression after a single injection. For
clinical trials, this construct can be administered both into the
bloodstream and locally into the cerebrospinal fluid.
This study demonstrated that gene therapy is highly efficacious
when applied at birth in presymptomatic nmd mice, defining a win-
dow of opportunity for treating SMARD1. However, SMARD1 chil-
dren are often asymptomatic at birth, and even if newborn screening
is feasible, it is crucial to investigate whether treatment is also effica-
cious when administered during a symptomatic phase. In the future,
we plan to conduct further experiments to define the effective thera-
peutic window. At first glance, there may be a possible narrow
window of opportunity for therapeutic intervention in SMARD1 on
the basis of findings from SMA. In a current gene therapy–based clin-
ical trial for SMA, patients are treated at diagnosis (when the first
symptoms appear, www.clinicaltrial.gov, NCT02122952). Even for
rare diseases such as SMARD1, newborn screening can become feasi-
ble when a treatment approach becomes effective. Recently, a combi-Nizzardo et al. Sci. Adv. 2015;1:e1500078 13 March 2015nation of exome and Sanger sequencing linked mutations affecting
IGHMBP2 to a milder phenotype similar to CMT2 (21); in these pa-
tients, no respiratory compromise occurs. In that study, although
IGHMBP2 protein levels were lower than those in control subjects,
they were significantly higher in cells from patients affected by CMT2
than in cells from SMARD1 patients, suggesting that differences in clin-
ical phenotype are related to IGHMBP2 protein levels. These data
broaden the number and spectrum of patients that can be treated with
our approach. No effective treatments are available for SMARD1; gene
therapy is a promising strategy, not only because it can reverse the
disease but also because it can prevent further deterioration.
Gene therapy approaches for SMA and SMARD1 are similar. The
diseases are both autosomal recessive disorders that affect mainly chil-
dren through loss-of-function mutations in a protein whose levels are
reduced, leading to the degeneration of motor neurons. Age of onset
and progressive paralysis are similar for the two disorders. Nevertheless,
some differences must be considered. First, the IGHMBP2 transgene is
larger than the SMN gene and can only be accommodated in linear
(not self-complementary) AAV9. However, we did not observe a sig-
nificant reduction in construct delivery or cell transfection efficacy,
and good rescue of the animals was achieved.
We further evaluated the effect of gene therapy in the context of
human disease, using human SMARD1 iPSC–derived motor neurons
as in vitro model. We observed rescue of the SMARD1 phenotype
after ex vivo genetic correction; improvements in cell survival, axonal
elongation, and growth cone formation confirmed that transferring
wild-type IGHMBP2 protects motor neurons from SMARD1-induced
degeneration in vitro. Previous studies (17, 18) that analyzed the sur-
vival and neurite length of primary motor neurons isolated from
SMARD1 mice did not show any difference in survival or axon length
compared to wild-type cells under basal conditions; survival was reduced
in a neurotoxic environment, which was provided by lipopolysaccharide-
activated microglial-conditioned medium. This discrepancy between
rodent data and data from human SMARD1 motor neurons, in which
reduced survival is evident, is mirrored in the SMA field. SMA murine
motor neurons do not show a decrease in survival that is apparent in
human SMA iPSC–derived motor neurons (24, 25). The reasons un-
derlying this discrepancy are unknown and are perhaps due to different
residual protein levels in combination with model-based differences
(species, transgenes, etc.). Our in vitro and in vivo experiments provide
an excellent rationale for clinical translation to patients.
In summary, IGHMBP2 gene therapy resulted in a highly effica-
cious rescue of survival and of the pathological phenotype of a SMARD1
mouse model. Systemic administration was necessary and sufficient to
target both neuronal and muscular pathological features. This study
confirms the feasibility of AAV-based technologies as effective thera-
peutic strategies for the treatment of genetic motor neuron diseases. In
particular, our results provide a proof of principle for the feasibility of
clinical translation of this strategy to treat SMARD1 and other genetic
motor neuron disorders.MATERIALS AND METHODS
AAV vectors
The open reading frame of the human IGMBPB2 cDNA (NCBI ac-
cession number NM_002080) was cloned into a shuttle plasmid con-
taining either AAV2 inverted terminal repeats (ITR) and the 1.6-kb7 of 10
R E S EARCH ART I C L ECBA promoter. Single-stranded AAV9-IGHMBP was produced by
transient transfection of HEK293 cells using a double-stranded AAV2-
ITR–based CBA vector with a plasmid encoding Rep2Cap9, as previ-
ously described (7), along with an adenoviral helper plasmid (pHelper,
Stratagene). Our serotype 9 sequence was verified by sequencing; it
was identical to the sequence previously described (7). Virus was
purified by two cesium chloride density gradient purification steps,
dialyzed against phosphate-buffered saline (PBS), formulated with
0.001% Pluronic F-68 to prevent virus aggregation, and stored at 4°C.
All vector preparations were titered through quantitative polymerase
chain reaction (PCR), using TaqMan technology (Life Technologies).
Vector purity was assessed by 4 to 12% SDS–polyacrylamide gel elec-
trophoresis (SDS-PAGE) and silver staining (Life Technologies). We
used a single-stranded AAV9 encoding GFP under control of the
CMV promoter (AAV9-GFP) to monitor transduction efficacy. As
a control, a third vector was generated in which the IGHMBP2 cDNA
was replaced with a noncoding sequence under the CBA promoter to
generate AAV9-null vector.
Animal procedures
The nmd mouse (B6.BKS Ighmbp2nmd-2 J/J) has a homozygous mu-
tation in Ighmbp2. Heterozygous mice were bred to generate mice
homozygous for the mutation. Homozygous nmd mutant mice and
wild-type littermates were used for the experiments and analyses.
The genotypes of the mice were confirmed using a PCR-based assay
with genomic DNA from tail biopsies, as described previously (6). All
transgenic animals were purchased from The Jackson Laboratory. All
animal experiments were approved by the University of Milan and
Italian Ministry of Health review boards, in compliance with U.S. Na-
tional Institutes of Health Guide for the Care and Use of Laboratory
Animals (15).
On P1, pups received one injection in the facial vein; the AAV9-
IGHMBP2/GFP dose was 5 × 1011 vg in 100 ml. Systemic injection was
performed with a 0.5-ml, 30-gauge insulin syringe (7, 11). As controls,
nmd mice received AAV9-null vector using the same dose and surgi-
cal procedure. The experimental groups included 17 AAV9-IGHMBP2-
nmdmice and 24 AAV9-null-nmdmice. A blinded examiner evaluated
the animals for weight, rotarod performance, survival record, and his-
tological evaluation. This study was designed so that littermates were
distributed equally between the AAV9-IGHMBP2 and AAV9-null
groups. Additional separate groups of animals (each composed of
six mice per time point per condition) were sacrificed for histological
analysis, quantification of motor neurons and axons, and muscle anal-
ysis. To test AAV9-IGHMBP2 efficiency, C57BL/6 mice were injected
directly in the gastrocnemius with 1 × 1010 vg AAV9-IGHMBP2, and
muscle was collected after 2 weeks.
Western blots
Western blot analysis for IGHMBP2 was performed as previously de-
scribed (18, 24). Briefly, frozen spinal cord specimens were homogen-
ized in radioimmunoprecipitation assay buffer [50 mM tris (pH 7.5),
150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS]
supplemented with protease inhibitor cocktail tablets (Roche). Protein
content was measured with the Lowry assay. Cell extracts fromHEK293
cells, wild-type iPSCs, and SMARD1 iPSCs were prepared 48 hours
after transfection. Forty micrograms of total protein was boiled in
Laemmli buffer for 5 min and separated on 8% SDS-PAGE. After elec-
trophoresis, proteins were transferred onto a nitrocellulose membrane,Nizzardo et al. Sci. Adv. 2015;1:e1500078 13 March 2015blocked with 5% bovine serum albumin (BSA) for 1 hour at room
temperature, and incubated with primary anti-IGHMBP2 peptide an-
tiserum (dilution 1:2500 in 5% BSA, provided by K. Grohmann, In-
stitute for Clinical Neurobiology University of Wuerzburg, Germany)
or anti-recombinant IGHMBP2 Ab (1:1500, Sigma-Aldrich) overnight
at 4°C. The next day, the nitrocellulose membrane was incubated with
anti-rabbit immunoglobulin G conjugated to horseradish peroxidase
(1:2700) (18). Finally, immune complexes were detected using chemi-
luminescence reagents. The nitrocellulose membrane was stripped and
reprobed with anti-actin monoclonal Ab (1:1000, Sigma-Aldrich) as a
control for equal loading.
Immunohistochemistry and NMJ staining
For histological analysis, 4-week-old animals were sacrificed, perfused,
and fixed with 4% paraformaldehyde in PBS (pH 7.4). The spinal cord
was isolated, immersed in paraformaldehyde solution for 1 hour fol-
lowed by incubation in 20% sucrose solution in PBS (pH 7.4) overnight,
and frozen in Tissue-Tek optimal cutting temperature compound with
liquid nitrogen. The quadriceps, gastrocnemius, and diaphragmmuscles
of each mouse were used for NMJ analysis.
Muscle fibers from the quadriceps, gastrocnemius, and diaphragm
muscles were stained as previously reported (22). Tissues were cryo-
sectioned and mounted on gelatinized glass slides. Every 10th section
of 20 mm was collected. All sections were washed with 1× PBS, then
blocked with 10% BSA in 1× PBS and 0.3% Triton X-100 for 1 hour at
room temperature. Primary Abs were added overnight at 4°C (neuro-
filament clone 2H3, 1:100, Developmental Studies Hybridoma Bank;
SMI32, 1:200, Millipore; anti-GFP 488, 1:400, Life Technologies).
Mouse and rabbit Abs conjugated with Alexa 488 or Alexa 546
(1:400, Life Technologies) or a-bungarotoxin 555 (1:500; Life Tech-
nologies) were used for 2 hours at room temperature as secondary
Abs when unconjugated primary Abs were used. For NMJ quantifica-
tion, a minimum of 100 NMJs from each muscle were randomly
selected and assessed under a microscope to determine the number
of denervated/degenerated NMJs for each muscle group per animal.
Motor neuron and axon counting
The lumbar spinal cord region of 4-week-old animals was processed
for paraffin embedding. Serial cross sections (12 mm thick) of the lum-
bar spinal cords were made, and every fifth section was processed and
Nissl-stained with methylene blue, as reported previously (17). The
number and diameter (soma) of all motor neurons counted in these
cross sections (n = 50 for each mouse) were analyzed. The sections
were analyzed at ×40 magnification in the anterior horn (either left
or right) for the presence of all neurons in that region. All cells were
counted within the ventral horn below an arbitrary horizontal line
drawn from the central canal. Only neuronal cells with at least one
nucleolus located within the nucleus were counted, as previously de-
scribed (17). The axonal count was performed as previously described
on semithin transverse sections stained with toluidine blue (15). Lum-
bar anterior roots were examined for axon counting on an optic mi-
croscope at ×60 magnification.
Morphological analysis of muscles and heart
For histological analysis of the periphery, the nitrogen-frozen quadri-
ceps, gastrocnemius, and diaphragm muscles from each 4-week-old
mouse were cryosectioned and stained with H&E to determine myofi-
ber dimensions, as previously reported (24). About 500 nonoverlapping8 of 10
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graphed at ×40 magnification. The cross-sectional area of each myo-
fiber was measured using Metamorph (Molecular Devices) to calculate
the overall average myofiber size per muscle for each animal. The
weights of hearts from AAV9-IGHMBP2-nmd, AAV9-null-nmd,
and wild-type mice were assessed in relation to body weight.
Neuromuscular evaluation and survival
All groups of nmd mice were monitored daily after injection of the
construct or vehicle for phenotypic hallmarks of disease. The investi-
gators that executed the functional assessment were blinded to treat-
ment status. Body weight was recorded, and motor function was tested
weekly with an accelerating rotarod device (4 to 40 rpm, Rota-Rod
7650, Ugo Basile). We recorded the length of time that each mouse
remained on the rotarod. Mortality was scored as age at death. The
animals were sacrificed when they were unable to right themselves
within 30 s of being placed in a supine position (17); examiners were
blinded to treatment status.
iPSCs, genetic correction, and differentiation into
motor neurons
iPSC lines were reprogrammed from SMARD1 fibroblasts and healthy
subjects (from EuroBioBank with appropriate ethical approval) using
a nonviral protocol (17). For genetic correction of the SMARD1 iPSC
line and the HEK293 line, 1 × 106 cells were transfected with 5 mg of
IGHMBP2 plasmid as previously described (26). To differentiate spi-
nal motor neurons, we followed a multistep protocol developed for
human embryonic stem cells and iPSCs (25), using SMARD1 and
wild-type iPSCs. Cells were plated with neuronal medium [Dulbecco’s
modified Eagle’s medium/F12 (Life Technologies)] supplemented with
MEM Non-Essential Amino Acids Solution (Life Technologies), N2
(Life Technologies), and heparin (2 mg/ml; Sigma-Aldrich), to which
retinoic acid (0.1 mM; Sigma-Aldrich) was added after 10 days for neu-
ral caudalization. Posteriorized neuroectodermal cells were collected at
day 17 and suspended for 1 week in the same medium with retinoic
acid (0.1 mM) and sonic hedgehog (100 to 200 ng/ml; R&D Systems),
followed by the addition of brain-derived neurotrophic factor and glial
cell line–derived neurotrophic factor on day 24 (10 ng/ml; PeproTech).
A centrifugation gradient was used to maximize motor neuron acqui-
sition (25). Cells were fixed and immunostained for quantification af-
ter culture for at least 24 hours.
Immunocytochemistry of iPSC-derived motor neurons
Cells were fixed in 4% paraformaldehyde for 10 min, permeabilized
with 0.25% Triton X-100, and blocked with 10% BSA in 1× PBS
and 0.3% Triton X-100 for 1 hour at room temperature. We incubated
the cells with primary Abs against IGHMBP2 (1:100, Sigma-Aldrich),
SMI-32 (1:100, Covance), or ChAT (goat polyclonal, 1:250, Millipore)
overnight and with fluorescein isothiocyanate–conjugated anti-rabbit
or anti-mouse (1:100, Dako) or Alexa Fluor 594–conjugated anti-goat
(1:400, Life Technologies) secondary Ab for 1.5 hours at room
temperature.
For all imaging, we used a confocal Leica LCS2 microscope. We
quantified motor neurons by identifying cells positive for motor neu-
ron markers in 10 randomly selected fields per well (three wells per
condition per experiment in five experiments). Morphometric axonal
length was measured using soma diameter and the distance between
two points.Nizzardo et al. Sci. Adv. 2015;1:e1500078 13 March 2015Statistical analysis
Kaplan-Meier survival analysis and log-rank test were used for surviv-
al comparisons. Growth curve and strength assay results were ana-
lyzed by analysis of variance (ANOVA) followed by Bonferroni’s
post hoc analysis for multiple comparisons. The number and size of
motor neurons, axon data, myofiber area, and heart measures were
evaluated with one-way ANOVA followed by Bonferroni’s post hoc
analysis. We used StatsDirect for Windows (version 2.6.4) for all
analyses, and the null hypothesis was rejected at the 0.05 level. We
analyzed differences in the results of morphometric axonal length
measurement (mean ± SEM for five independent experiments) with
the Kolmogorov-Smirnov test (www.physics.csbsju.edu/stats/KS-test.
n.plot_form.html).SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/content/
full/1/2/e1500078/DC1
Fig. S1. Validation of IGHMBP2 constructs in vitro and in vivo.
Fig. S2. AAV9-IGHMBP2 administration ameliorates SMARD1 cardiomyopathy.
Movie S1. Gross appearance of an AAV9-IGHMBP2–treated nmd mouse.REFERENCES AND NOTES
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